2026 Q1 -tulosraportti
43 päivää sitten
‧26 min
1,00 NOK/osake
Viimeisin osinko
10,77%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 992 | - | - | ||
| 8 | - | - | ||
| 2 650 | - | - | ||
| 894 | - | - | ||
| 600 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 24.4. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 31.10.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 päivää sittenIn response to the comment below on the forum, I have found an index showing metformin prices in India. The trend shows that it has risen sharply after the war in Iran broke out in March/April, and I assume that the price in the rest of the world has also risen accordingly. I found no other index showing the prices, but the India prices are in the index below. Perhaps someone else has more relevant prices?
·1 päivä sittenVistin probably has around 80% of its sales to Europe. Uncertain how prices are there compared to India, but the graph showing prices in India is quite in line with Vistin's revenue per kg metformin sold in EUR historically. One can therefore assume that the trend in metformin prices is similar in Europe as in India. Vistin had a peak in 3q/4q 2022 at EUR 8.90/kg with a decrease since then to EUR 6.21/kg and EUR 6.48/kg respectively in 4q25 and 1q26. If prices have shot up in India to 2023 levels, Vistin should be able to sell its batches at around EUR 7.50/kg in 2q/3q. With a high inventory, the cost per kg should not increase significantly, and Vistin's margins could reach up to 70%.
·30.4. · MuokattuA huge block sale today of 425.000 shares at price 22 per share, total 9.3 mill. https://investorprat.com/VISTN#blocktrades-section
·6.5. · MuokattuBUYER: SURFSIDE HOLDING AS (+425.000), which is 100% owned by Morten Eivindssøn Astrup, who lives in Switzerland, and is one of the brothers of the well-known Høyre-politician Nikolai Eivindssøn Astrup, who, together with his brother Henning and father Eivind Haraldssøn Astrup, owns nearly 100% of PACTUM VEKST AS, which is the 3rd largest VISTIN shareholder (2.991.773 = 6.75%), and whose chairman of the board Espen Weyergang Marcussen is a board member of VISTIN. Does it smell a bit like insider trading? Morten Eivindssøn Astrup regularly appears in Finansavisen where he speaks highly of the companies he is a shareholder in, but NEVER a word about VISTIN where he is now the 5th largest shareholder (952.960 = 2.15%) SELLERS: TIGERSTADEN AS (-300.000), which is 100% owned by the well-known investor Ketil Grim Skorstad, and BOOLEAN AS (-125.000), which is 51% owned by Ketil Grim Skorstad.- ·16.4. · MuokattuNice movement in this recently, without there being any more interest or writings about it. We know there will be a dividend, but is there perhaps an expectation that q1 will be good? I can't find a metformin price index that gives a good picture of what we can expect in terms of earnings margins, but perhaps the prices of metformin have also risen after the war broke out! Does anyone else know?·5.5.1.5kr dividend, which corresponds to 6.6% dividend yield at a price of 22.6. I also expect that they will maintain this, while actively looking for external growth areas + can increase their own production.
- ·21.2. · MuokattuSignificant insider purchase by CEO Magnus Tolleshaug https://newsweb.oslobors.no/message/666416 Magnus Tolleshaug, Chief Executive Officer in Vistin Pharma ASA, and a primary insider, has on 20'th of February 2026 purchased 30.000 shares in Vistin Pharma ASA at an average price of NOK 21,10 per share. Following this purchase Magnus Tolleshaug holds 105.000 shares in Vistin Pharma ASA.·21.2.Good trade there, indicates that q1 and 2026 offer growth and good results!
·23.2.Does anyone, by the way, know if they have the possibility to expand capacity in the current factory in Kragerø, or do they then possibly have to rent or build new premises? The reason I'm asking is that the strategy is to grow beyond Metformin, which I can't interpret as anything other than another API from CF pharma. They have probably stated this directly, I would think.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
43 päivää sitten
‧26 min
1,00 NOK/osake
Viimeisin osinko
10,77%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sittenIn response to the comment below on the forum, I have found an index showing metformin prices in India. The trend shows that it has risen sharply after the war in Iran broke out in March/April, and I assume that the price in the rest of the world has also risen accordingly. I found no other index showing the prices, but the India prices are in the index below. Perhaps someone else has more relevant prices?·1 päivä sittenVistin probably has around 80% of its sales to Europe. Uncertain how prices are there compared to India, but the graph showing prices in India is quite in line with Vistin's revenue per kg metformin sold in EUR historically. One can therefore assume that the trend in metformin prices is similar in Europe as in India. Vistin had a peak in 3q/4q 2022 at EUR 8.90/kg with a decrease since then to EUR 6.21/kg and EUR 6.48/kg respectively in 4q25 and 1q26. If prices have shot up in India to 2023 levels, Vistin should be able to sell its batches at around EUR 7.50/kg in 2q/3q. With a high inventory, the cost per kg should not increase significantly, and Vistin's margins could reach up to 70%.
- ·30.4. · MuokattuA huge block sale today of 425.000 shares at price 22 per share, total 9.3 mill. https://investorprat.com/VISTN#blocktrades-section·6.5. · MuokattuBUYER: SURFSIDE HOLDING AS (+425.000), which is 100% owned by Morten Eivindssøn Astrup, who lives in Switzerland, and is one of the brothers of the well-known Høyre-politician Nikolai Eivindssøn Astrup, who, together with his brother Henning and father Eivind Haraldssøn Astrup, owns nearly 100% of PACTUM VEKST AS, which is the 3rd largest VISTIN shareholder (2.991.773 = 6.75%), and whose chairman of the board Espen Weyergang Marcussen is a board member of VISTIN. Does it smell a bit like insider trading? Morten Eivindssøn Astrup regularly appears in Finansavisen where he speaks highly of the companies he is a shareholder in, but NEVER a word about VISTIN where he is now the 5th largest shareholder (952.960 = 2.15%) SELLERS: TIGERSTADEN AS (-300.000), which is 100% owned by the well-known investor Ketil Grim Skorstad, and BOOLEAN AS (-125.000), which is 51% owned by Ketil Grim Skorstad.
- ·16.4. · MuokattuNice movement in this recently, without there being any more interest or writings about it. We know there will be a dividend, but is there perhaps an expectation that q1 will be good? I can't find a metformin price index that gives a good picture of what we can expect in terms of earnings margins, but perhaps the prices of metformin have also risen after the war broke out! Does anyone else know?·5.5.1.5kr dividend, which corresponds to 6.6% dividend yield at a price of 22.6. I also expect that they will maintain this, while actively looking for external growth areas + can increase their own production.
- ·21.2. · MuokattuSignificant insider purchase by CEO Magnus Tolleshaug https://newsweb.oslobors.no/message/666416 Magnus Tolleshaug, Chief Executive Officer in Vistin Pharma ASA, and a primary insider, has on 20'th of February 2026 purchased 30.000 shares in Vistin Pharma ASA at an average price of NOK 21,10 per share. Following this purchase Magnus Tolleshaug holds 105.000 shares in Vistin Pharma ASA.·21.2.Good trade there, indicates that q1 and 2026 offer growth and good results!·23.2.Does anyone, by the way, know if they have the possibility to expand capacity in the current factory in Kragerø, or do they then possibly have to rent or build new premises? The reason I'm asking is that the strategy is to grow beyond Metformin, which I can't interpret as anything other than another API from CF pharma. They have probably stated this directly, I would think.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 992 | - | - | ||
| 8 | - | - | ||
| 2 650 | - | - | ||
| 894 | - | - | ||
| 600 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 24.4. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 31.10.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
2026 Q1 -tulosraportti
43 päivää sitten
‧26 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 24.4. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 31.10.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 |
1,00 NOK/osake
Viimeisin osinko
10,77%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sittenIn response to the comment below on the forum, I have found an index showing metformin prices in India. The trend shows that it has risen sharply after the war in Iran broke out in March/April, and I assume that the price in the rest of the world has also risen accordingly. I found no other index showing the prices, but the India prices are in the index below. Perhaps someone else has more relevant prices?·1 päivä sittenVistin probably has around 80% of its sales to Europe. Uncertain how prices are there compared to India, but the graph showing prices in India is quite in line with Vistin's revenue per kg metformin sold in EUR historically. One can therefore assume that the trend in metformin prices is similar in Europe as in India. Vistin had a peak in 3q/4q 2022 at EUR 8.90/kg with a decrease since then to EUR 6.21/kg and EUR 6.48/kg respectively in 4q25 and 1q26. If prices have shot up in India to 2023 levels, Vistin should be able to sell its batches at around EUR 7.50/kg in 2q/3q. With a high inventory, the cost per kg should not increase significantly, and Vistin's margins could reach up to 70%.
- ·30.4. · MuokattuA huge block sale today of 425.000 shares at price 22 per share, total 9.3 mill. https://investorprat.com/VISTN#blocktrades-section·6.5. · MuokattuBUYER: SURFSIDE HOLDING AS (+425.000), which is 100% owned by Morten Eivindssøn Astrup, who lives in Switzerland, and is one of the brothers of the well-known Høyre-politician Nikolai Eivindssøn Astrup, who, together with his brother Henning and father Eivind Haraldssøn Astrup, owns nearly 100% of PACTUM VEKST AS, which is the 3rd largest VISTIN shareholder (2.991.773 = 6.75%), and whose chairman of the board Espen Weyergang Marcussen is a board member of VISTIN. Does it smell a bit like insider trading? Morten Eivindssøn Astrup regularly appears in Finansavisen where he speaks highly of the companies he is a shareholder in, but NEVER a word about VISTIN where he is now the 5th largest shareholder (952.960 = 2.15%) SELLERS: TIGERSTADEN AS (-300.000), which is 100% owned by the well-known investor Ketil Grim Skorstad, and BOOLEAN AS (-125.000), which is 51% owned by Ketil Grim Skorstad.
- ·16.4. · MuokattuNice movement in this recently, without there being any more interest or writings about it. We know there will be a dividend, but is there perhaps an expectation that q1 will be good? I can't find a metformin price index that gives a good picture of what we can expect in terms of earnings margins, but perhaps the prices of metformin have also risen after the war broke out! Does anyone else know?·5.5.1.5kr dividend, which corresponds to 6.6% dividend yield at a price of 22.6. I also expect that they will maintain this, while actively looking for external growth areas + can increase their own production.
- ·21.2. · MuokattuSignificant insider purchase by CEO Magnus Tolleshaug https://newsweb.oslobors.no/message/666416 Magnus Tolleshaug, Chief Executive Officer in Vistin Pharma ASA, and a primary insider, has on 20'th of February 2026 purchased 30.000 shares in Vistin Pharma ASA at an average price of NOK 21,10 per share. Following this purchase Magnus Tolleshaug holds 105.000 shares in Vistin Pharma ASA.·21.2.Good trade there, indicates that q1 and 2026 offer growth and good results!·23.2.Does anyone, by the way, know if they have the possibility to expand capacity in the current factory in Kragerø, or do they then possibly have to rent or build new premises? The reason I'm asking is that the strategy is to grow beyond Metformin, which I can't interpret as anything other than another API from CF pharma. They have probably stated this directly, I would think.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 992 | - | - | ||
| 8 | - | - | ||
| 2 650 | - | - | ||
| 894 | - | - | ||
| 600 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt